MedPath

Commons, Marty

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Phase 3
Completed
Conditions
Relapsing Multiple Sclerosis
Interventions
Drug: Teriflunomide capsule
Drug: Ofatumumab subcutaneous injection
Drug: Teriflunomide-matching placebo capsules
Drug: Matching placebo of ofatumumab subcutaneous injections
First Posted Date
2016-06-07
Last Posted Date
2021-10-01
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
930
Registration Number
NCT02792218
Locations
🇬🇧

Novartis Investigative Site, London, United Kingdom

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Phase 3
Completed
Conditions
Relapsing Multiple Scelrosis
Interventions
Drug: Ofatumumab subcutaneous injection
Drug: Teriflunomide capsule
Drug: Teriflunomide-matching placebo capsules
Drug: Matching placebo of ofatumumab subcutaneous injections
First Posted Date
2016-06-07
Last Posted Date
2021-11-22
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
955
Registration Number
NCT02792231
Locations
🇬🇧

Novartis Investigative Site, London, United Kingdom

A Registry of Patients With Moderate to Severe Plaque Psoriasis

Active, not recruiting
Conditions
Psoriasis
Interventions
Drug: Secikinumab
First Posted Date
2016-05-30
Last Posted Date
2024-11-22
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
2384
Registration Number
NCT02786186
Locations
🇵🇦

Novartis Investigative Site, Panama, Panama

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

Phase 2
Completed
Conditions
Primary Sjögren's Syndrome
Interventions
Drug: CDZ173
Drug: Placebo
First Posted Date
2016-05-18
Last Posted Date
2021-01-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
30
Registration Number
NCT02775916
Locations
🇭🇺

Novartis Investigative Site, Debrecen, Hungary

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site

Phase 3
Completed
Conditions
Axial Spondyloarthritis
Enthesitis
Psoriatic Arthritis
Interventions
Biological: Secukinumab
Drug: Secukinumab Placebo
First Posted Date
2016-05-13
Last Posted Date
2021-05-03
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
204
Registration Number
NCT02771210
Locations
🇬🇧

Novartis Investigative Site, Tyne And Wear, United Kingdom

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Phase 4
Completed
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
Drug: LCZ696
Drug: Enalapril
Drug: Placebo matching enalapril
Drug: Placebo matching LCZ696
First Posted Date
2016-05-11
Last Posted Date
2021-10-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
201
Registration Number
NCT02768298
Locations
🇩🇪

Novartis Investigative Site, Wuppertal, Germany

Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients

Phase 2
Terminated
Conditions
Transplant Associated Microangiopathy TAM
Interventions
Drug: LFG316 active drug
Other: Standard of care treatment
First Posted Date
2016-05-05
Last Posted Date
2021-01-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
7
Registration Number
NCT02763644
Locations
🇩🇪

Novartis Investigative Site, Heidelberg, Germany

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis

Phase 4
Completed
Conditions
Ankylosing Spondylitis
Interventions
Drug: Secukinumab (AIN457) 150 mg s.c.
Drug: Placebo - Secukinumab (AIN457) 150 mg s.c.
First Posted Date
2016-05-05
Last Posted Date
2021-10-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
211
Registration Number
NCT02763046
Locations
🇩🇪

Novartis Investigative Site, Trier, Germany

Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects

Phase 2
Completed
Conditions
Atopic Asthma
Interventions
Procedure: Blood sample
Device: POCT device
First Posted Date
2016-05-02
Last Posted Date
2016-11-15
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
193
Registration Number
NCT02758548
Locations
🇬🇧

Novartis Investigative Site, Manchester, United Kingdom

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

First Posted Date
2016-04-29
Last Posted Date
2016-11-08
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT02756663
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy